Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status [Yahoo! Finance]
Soligenix, Inc. (SNGX)
NASDAQ:AMEX Investor Relations:
soligenix.com/investors
Company Research
Source: Yahoo! Finance
potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the treatment of Behet's disease, reinforcing both the promise of the therapy and the company's broader development strategy. Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Soligenix announced that the European Commission granted orphan drug designation to SGX945 for the treatment of Behet's disease. SGX945 is based on dusquetide, a synthetic peptide belonging to a class of compounds known as innate defense regulators. Investor Brand Network Designations from established global organizations such as the European Commission carry meaningful implications for biotechnology companies. Orphan drug design
Show less
Read more
Impact Snapshot
Event Time:
SNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNGX alerts
High impacting Soligenix, Inc. news events
Weekly update
A roundup of the hottest topics
SNGX
News
- Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results [Yahoo! Finance]Yahoo! Finance
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy [Yahoo! Finance]Yahoo! Finance
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy [TheStreet.com]TheStreet.com
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and TherapyPR Newswire
- Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
SNGX
Sec Filings
- 4/3/26 - Form EFFECT
- 4/3/26 - Form EFFECT
- 4/3/26 - Form EFFECT
- SNGX's page on the SEC website